This inhibition also imparts resistance to sorafenib-induced ferroptosis on hepatocellular carcinoma cells by boosting the activity of the NF-κB/LCN2 (lipocalin 2) pathway (245). Here, LCN2 is linked to hepatocellular carcinoma.